# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- SEC Filing
Piper Sandler analyst Joseph Catanzaro initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Overweight rating and...
- SEC Filing
-SEC Filing
HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price ta...
Maxim Group analyst Jason McCarthy maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price target from ...
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of ...